Vasili Balios

The Week's Biggest Signal: Gene Editing Is Starting to Look Like a Product Category For years, gene editing has been judged mainly by whether it could work at all. Could CRISPR cut the right target? Could a base editor fix a disease-linked letter? Could a therapy produce a measurable effect in animals or a small group of patients? That question is no longer enough. This week, the strongest signal came from Intellia Therapeutics, which reported positive Phase 3 results for lonvoguran...

The Week's Biggest Signal: Precision Now Means Understanding Context. Gene editing has spent years proving that it can change DNA. That part is no longer the main question. The more important question now is whether it can make the right change in the right biological setting, at a cost and scale that matter outside a headline-grabbing first patient. That is why the strongest source this week was not a flashy clinical trial result, but a Nature comment published on April 21 about how...

The Week's Biggest Signal: Gene Editing Is Being Forced to Grow Up For years, the story of genetic engineering has been about what might be possible. This week felt different. The most interesting developments were not just flashy demonstrations of editing power. They were signs that the field is being pushed toward something harder and more valuable: real clinical usefulness. The clearest example came from a personalized CRISPR-Cas9 strategy for beta-thalassaemia, published in Nature on...